Analytical quality by design approach for the development of high‐performance liquid chromatography method for simultaneous analysis of metformin and sitagliptin in the presence of major degradation products

An analytical quality by design‐based high‐performance liquid chromatography method for determining metformin (MET) and sitagliptin (SIT) in stress‐degraded samples was developed and validated. The analytical target profile and risk assessment‐driven critical method variables, for example, pH, % aqueous, and buffer concentration, were studied for their effect on method responses of retention time and resolution using a central composite design. The correlation regression coefficient was more than 0.8, and variables interaction was significant on method responses with curvature effect. The method operable design region afforded an aqueous range of 55%–70% and an ortho ‐phosphoric acid buffer of 0.1% with a pH of 3.0–4.0 as a robust region for the suitable method performance characteristics. The separation of MET and SIT from their degradants ( m/z 85.0509; m/z 193.0694) on the C 8 column was achieved using a mobile phase consisting of 0.1% ortho ‐phosphoric acid and methanol (60:40% v/v; pH 3.0). The optimized method eluted MET and SIT at 4.3 ± 0.2 and 7.1 ± 0.2 min, respectively, with acceptable specificity and resolution. The linearity ranges of 25–250 μg/mL (r 2 : 0.9982) and 5–50 μg/mL (r 2 : 0.9989) was established for MET and SIT, respectively. The % recovery (98.81%–102.17%), precision (0.55%–1.65%), and robustness study for method variables were acceptable.